2 Bargain Stocks to Buy For 2023 And Beyond

NASDAQ: VRTX | Vertex Pharmaceuticals Inc. News, Ratings, and Charts

VRTX – Despite widespread headwinds, experts believe the U.S. economy might avoid a recession this year. Additionally, value stocks have been outperforming growth, and we think Vertex Pharmaceuticals (VRTX) and Kroger (KR), which seem to be trading at discounts, could be ideal buys for 2023 and beyond. Keep reading…

U.S. inflation remains alarmingly high despite the Fed’s relentless efforts to tame it. Although inflation has shown signs of slowing over the past few months, Fed officials have indicated further rate hikes ahead.

While the market witnessed a bout of selloffs since last year, this offers the right opportunity to scoop up fundamentally solid stocks, Vertex Pharmaceuticals Incorporated (VRTX - Get Rating) and The Kroger Co. (KR - Get Rating), which seem to be trading at a discount.

On the other hand, market sentiments have been improving lately. According to market veteran Ed Yardeni, the U.S. has a 60% chance of avoiding a recession, and stocks could notch a new all-time high this year as the market rebounds.

In addition, value or bargain stocks are expected to maintain their winning streak against growth stocks amid rising rates. Goldman Sachs’ experts believe value stocks’ outperformance to continue in 2023.

Investors’ interest in value stocks is evident from the SPDR Portfolio S&P 500 Value ETF’s (SPYV) 4.2% gains over the past six months.

So, let’s delve deeper into these stocks mentioned above:

Vertex Pharmaceuticals Incorporated (VRTX - Get Rating)

Biotechnology company VRTX develops and commercializes therapies for treating cystic fibrosis.

VRTX’s forward P/E of 22.32x is 17.4% lower than the industry average of 27.03x. Its trailing-12-month EV/EBITDA of 14.30x is 6.3% lower than the industry average of 15.27x.

Its trailing-12-month gross profit margin of 59.60% is 6.5% higher than the industry average of 55.99%, while its trailing-12-month EBITDA margin of 50.69% is substantially higher than the industry average of 3.74%.

VRTX’s net product revenues came in at $2.30 billion for the fourth quarter that ended December 31, 2022, up 11.1% year-over-year. Its non-GAAP net income increased 25.9% year-over-year to $978 million, while its non-GAAP EPS came in at $3.76, representing a 24.5% year-over-year rise.

Analysts expect VRTX’s revenue to increase 8.6% year-over-year to $9.70 billion in the current fiscal year, 2023. Its EPS is expected to rise 5.8% per annum for the next five years. It surpassed EPS estimates in all four trailing quarters. Over the past year, the stock has gained 26.2% to close the last trading session at $290.29.

VRTX’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, which indicates a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

VRTX has an A grade for Quality and a B for Value. Within the Biotech industry, it is ranked #3 out of 400 stocks. Click here for the additional POWR Rating for Growth, Momentum, Stability, and Sentiment for VRTX.

The Kroger Co. (KR - Get Rating)

KR operates as a retailer in the United States. The company operates combination food and drug stores, multi-department stores, marketplace stores, and price-impact warehouses.

KR’s forward P/E of 12.72x is 35.3% lower than the industry average of 19.64x. Its forward EV/Sales of 0.34x is 79.4% lower than the industry average of 1.64x.

Its trailing-12-month ROCE and ROTC of 24.00% and 9.38% are 143.6% and 52.2% higher than the industry averages of 9.85% and 6.17%.

KR’s sales came in at $34.20 billion for the third quarter that ended November 5, 2022, up 7.3% year-over-year. Its current assets came in at $13.40 billion, up marginally year-over-year.

Street expects KR’s revenue to increase 7.6% year-over-year to $148.40 billion in 2023. Its EPS is expected to be 12.8% year-over-year to $4.15 in 2023. It surpassed EPS estimates in all four trailing quarters. KR’s shares have lost marginally intraday to close the last trading session at $43.14.

It’s no surprise that KR has an overall A rating, which equates to a Strong Buy in our proprietary rating system. In addition, it has a B grade for Growth, Value, and Quality.

KR is ranked #9 out of 38 stocks in the A-rated Grocery/Big Box Retailers industry. Get additional POWR Ratings for KR (Momentum, Stability, and Sentiment) here.

What To Do Next?

Get your hands on this special report:

3 Stocks To DOUBLE This Year

What gives these stocks the right stuff to become big winners, even in this brutal stock market?

First, because they are all low-priced companies with the most upside potential in today’s volatile markets.

But even more important is that they are all top Buy rated stocks according to our coveted POWR Ratings system, and they excel in key areas of growth, sentiment and momentum.

Click below now to see these three exciting stocks that could double or more in the year ahead.

3 Stocks To DOUBLE This Year

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


VRTX shares were trading at $289.87 per share on Wednesday morning, down $0.42 (-0.14%). Year-to-date, VRTX has gained 0.38%, versus a 3.40% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
VRTXGet RatingGet RatingGet Rating
KRGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Why is Stock Market Outlook So Uncertain?

The S&P 500 (SPY) has quickly pushed back from the highs and once again on the verge of a break below the 100 day moving average. Why is this happening? And what comes next? 40 year investment veteran Steve Reitmeister shares his view and top stocks in the commentary that follows...

3 Under-the-Radar Tech Stocks Quietly Powering the Digital Revolution

The technology industry's future seems promising, owing to increasing investments and rising worldwide demand for better products. Hence, investing in fundamentally stable tech stocks, Motorola (MSI), Power Integrations (POWI), and CI&T (CINT) could be the move for investors looking to capitalize on the sector's growth. Read on…

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading...

3 Metaverse Stocks Building the Virtual Economy

The metaverse isn’t just a futuristic fantasy; it’s shaping up to be the next big digital economy. As digital spaces evolve into thriving marketplaces, companies like Apple (AAPL), NVIDIA Corp. (NVDA), and Meta Platforms (META) are building the foundation for this new era. Thus, investing in them could be rewarding. Read more…

Trump or the Fed More Important to Stock Investors?

The S&P 500 (SPY) is flirting with new highs once again. But it is not very clear what is driving these stock price gains. That is why Steve Reitmeister shares his latest views including a market outlook, trading plan and top picks to stay on the right side of the action.

Read More Stories

More Vertex Pharmaceuticals Inc. (VRTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VRTX News